← FDA DRUG APPROVALS

FDA ANDA · ANDA201835

METHYLPREDNISOLONE ACETATE

Sponsor: SAGENT PHARMS INC

APPLICATION
ANDA201835
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-27
LATEST ACTION
2023-12-12
ROUTE
INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription, Discontinued

Products

METHYLPREDNISOLONE ACETATEPrescription
METHYLPREDNISOLONE ACETATE 80MG/ML · INJECTABLE · INJECTION
METHYLPREDNISOLONE ACETATEDiscontinued
METHYLPREDNISOLONE ACETATE 20MG/ML · INJECTABLE · INJECTION
METHYLPREDNISOLONE ACETATEPrescription
METHYLPREDNISOLONE ACETATE 40MG/ML · INJECTABLE · INJECTION

Approval history

2023-12-12Labeling · Supplement 5 · standardAP
2020-08-07Labeling · Supplement 1 · standardAP
2018-06-27Not Applicable · OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →